CA-PATIENT-SAFETY
3.2.2020 15:02:07 CET | Business Wire | Press release
Patient Safety Movement Foundation is urging clinicians, patient advocates, hospitals and medical technology companies to support Data Sharing as part of the 2020 Federal Health IT plan.
“One of the key ways to combat preventable patient deaths in hospitals is for companies to share their data in a HIPAA compliant manner instead of hoarding it for profit. The plan proposed by the Office of the National Coordinator for Health Information Technology will help create the personalized patient data superhighway we need to reduce and eliminate preventable deaths in our hospitals,” said Joe Kiani, Founder of the Patient Safety Movement and Founder, Chairman, and CEO of Masimo. “If we block patient data, no one can create algorithms that can warn clinicians of potential problems before they happen. We are already losing way too many people to medical errors in our hospitals each year, and we can’t delay this any longer.”
Several years ago, a young man named Rory Staunton died of Sepsis because of exactly this type of fragmented medical information system. “On Tuesday, my son Rory was playing basketball at a school gym, fell and cut himself. His teacher put a bandaid on it. He died 5 days later from Sepsis,” said Orlaith Staunton. “Despite having a high heart rate for his size as measured by a patient monitor at his pediatrician’s office and a high white blood cell count that was detected in the Emergency Department’s blood test machine, Rory was sent home because no one had all of the details of his problems and care. They couldn’t put the high heart rate and high white blood cell count together with the full story to realize he had Sepsis. Had we had data sharing allowing a complete view of his history and condition or the benefit of a predictive algorithm to track my son’s case when he was connected to various monitors and blood test machines, he would probably be alive today.”
Since the founding of the Patient Safety Movement, nearly 100 companies have signed the voluntary Open Data Pledge, including Baxter, Cerner, Dräger, Edwards Lifesciences, GE Healthcare, IBM, Masimo, Medtronic, Oracle, Philips and Zoll. Complete list below. For more information on how you can sign the Pledge, please visit www.patientsafetymovement.org . For more information regarding the 2020 Federal Health IT Plan, please visit https://www.healthit.gov/sites/default/files/page/2020-01/2020-2025FederalHealthIT%20StrategicPlan_0.pdf .
Companies that have signed the Patient Safety Movement Foundation Open Data Pledge (alphabetical order):
AccuHealth Group |
Admetsys |
AirStrip |
Ambient Clinical |
Baxter |
BD Intelliport (formerly CRISI Medical Systems) |
Bernoulli Health |
Beterra Health |
BIOIN SOLUCIONES SAS |
Biovigil |
BrainStem Biometrics |
caresyntax, Inc. |
Cercacor |
Cerner |
Cheetah Medical, Inc. |
Clean Hands-Safe Hands |
CNSystems Medizintechnik AG |
Codonics |
CrossChx |
DebMed |
Decisio Health |
Deltex Medical |
Doctella |
Dräger |
DynaLabs LLC |
11 Health |
EarlySense |
eBroselow, LLC |
Edwards LifeSciences |
Forcare |
FUJIFILM SonoSite, Inc. |
GE Healthcare |
Genomi-k |
Hamilton Medical AG |
Handtevy-Pediatric Emergency Standards, Inc. |
Healthcentrix |
Heartin Inc. |
HeROScore |
Hiteks |
IBM Watson Health |
ICUcare |
Informs Inc. |
Innara Health |
Iradimed |
Jvion |
KnectIQ Inc. |
Kolkin |
LiDCO Group |
LumiraDX USA Inc. |
Magnamed Tecnologia Médica S/A. |
Masimo |
Mdoloris Medical Systems |
Medi+Sign |
Medical Simulation Corporation |
MediSafe Inc |
Medtronic |
Mindray |
Modulated Imaging |
Monarch Medical Technologies |
Neosim |
NeurOptics |
Oracle |
Patient Valet |
Pegwin |
PeraHealth |
PerceptiMed |
Philips Healthcare |
Phoenix Medical Systems Pvt. Ltd. |
Pieces Technology |
Pooyandegan Rah Saadat Co.,Ltd. |
Rapid Healthcare |
Redivus Health |
RGP Healthcare |
RightPatient |
RPRD Diagnostics |
SafeCare Group |
SafeStart Medical |
SenTec Inc. |
Smiths Medical |
Sotera Wireless |
Stanley Healthcare |
Stibo Systems |
SurgiCount Medical |
SwipeSense |
Talis Clinical |
ThermoMedics, Inc. |
Triton Electronic Systems LTD |
True Process |
Vitalacy (FORMERLY Hygenix) |
Welch Allyn (acquired by Hill-Rom) |
West-Com Nurse Call Systems, Inc |
ZOLL Medical |
About Patient Safety Movement Foundation
Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
